Gefitinib

• Mechanism of Action
• Inhibits epidermal growth factor receptor (EGFR), a transmembrane amino acid receptor tyrosine kinase found in approximately 15% of non small cell lung cancers.
  EGFR mutations affect downstream signalling pathways resulting in cell proliferation
  Inhibition of these receptors disrupts this proliferation pathway.

Clinical Use

• • Indication
  • Advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation
• • Adverse Effects